Apremilast APIs, developed by Loncom Pharma, offer an advanced solution for treating autoimmune conditions such as psoriasis and psoriatic arthritis. This category encompasses high-quality Apremilast compounds, characterized by their potent inhibition of PDE4, reducing inflammation and providing relief to patients.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
